Print
Email
Print Edition StoriesMonday, September 28, 2009
Covidien to buy Aspect Medical for $210M
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
Covidien plc has announced an agreement to buy Norwood-based brain-monitoring device company Aspect Medical Systems Inc. for about $210 million, the two companies reported today. Covidien noted associated restructuring charges but did not indicate the number of expected layoffs resulting from the merger.
Covidien is a medical device and pharmaceutical maker based in Dublin, with its U.S. headquarters in Mansfield. The company will acquire Aspect Medical in an all-cash tender offer and second-step merger that is expected to be completed by the end of 2009. As a result, Aspect will become part of the Oximetry and Monitoring product line in the Medical Devices segment
Covidien will benefit from the acquisition by adding Aspect’s brain monitoring technology, according to a released statement by Pete Wehrly, Covidien president of Respiratory & Monitoring Solutions. Covidien’s overall strategy is to expand in markets just outside of its existing business.
Aspect Medical (Nasdaq: ASPM) says its brain-monitoring system, called bispectral index technology, has been used to assess 29 million patients. A primary use of the technology is to monitor brain activity in patients undergoing general anesthesia or deep sedation, according to the firm.
Covidien (NYSE: COV) has sold several of its product lines recently, and officials said the company has sold its assets in order to “streamline its portfolio” and focus instead on higher-margin businesses.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
